Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Triple Negative Breast Neoplasms × AC protocol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 6 Triple Negative Breast Neoplasms 1 Locally Advanced HER2-negative Breast Cancer 1 Hyperthermia 1

Interventions

Carboplatin 76 pembrolizumab 73 Paclitaxel 62 Cyclophosphamide 53 Capecitabine 34 Doxorubicin 33 130-nm albumin-bound paclitaxel 27 Taxes 23 Cisplatin 21 Docetaxel 20 Albumin-Bound Paclitaxel 20 Drug Therapy 18 sacituzumab govitecan 17 Epirubicin 17 camrelizumab 16 atezolizumab 16 olaparib 15 durvalumab 15 Bevacizumab 15 Gemcitabine 14 eribulin 13 Specimen Handling 13 Radiotherapy 13 toripalimab 12 Biopsy 12 Magnetic Resonance Spectroscopy 11 Everolimus 10 talazoparib 9 liposomal doxorubicin 9 apatinib 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04248998 2023-01-18

BREAKFAST

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Unknown

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡